Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease

Open access

Abstract

Background: There is currently a lack of reliable and easily accessible biomarkers predicting cognitive decline in Alzheimer’s disease (AD). Synaptic dysfunction and loss occur early in AD and synaptic loss measured in the brain tissue and by PET are closely linked to cognitive decline, rendering synaptic proteins a promising target for biomarker development. Methods: We used novel Simoa assays to measure cerebrospinal fluid (CSF) levels of two synaptic biomarker candidates, postsynaptic density protein 95 (PSD-95/DLG4), and the presynaptically localized synaptosomal-associated protein 25 (SNAP-25), as well as neurogranin (Ng), an established postsynaptic biomarker. CSF samples from two well-characterized cohorts ( n =178 and n =156) were selected from banked samples obtained from diagnostic lumbar punctures containing subjects with amyloid-ß (Aß) positive AD, subjects with non-AD neurodegenerative diseases, subjects with other neurological conditions, and healthy controls (HC). Results: All subjects had detectable CSF levels of PSD-95, SNAP-25, and Ng. CSF levels of PSD-95, SNAP-25, and Ng were all correlated, with the strongest correlation between the presynaptic SNAP-25 and the postsynaptic neurogranin. AD subjects had on average higher concentrations of all three synaptic markers compared to those with non-AD neurodegenerative diseases, other neurological disorders, and HCs. Increased CSF levels of PSD-95, SNAP-25, and Ng were, however, not specific for AD and were present in sporadic cases with inflammatory or vascular disorders as well. High CSF levels of PSD-95 were also observed in a few subjects with other neurodegenerative disorders. Conclusion: The data establishes PSD-95 as a promising CSF marker for neurodegenerative disease synaptic pathology, while SNAP-25 and Ng appear to be somewhat more specific for AD. Together, these synaptic markers hold promise to identify early AD pathology, to correlate with cognitive decline, and to monitor responses to disease-modifying drugs reducing synaptic degeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-022-01002-x

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Correlations between CSF levels of PSD-95, SNAP-25, and neurogranin stratified by diagnostic group
Fig. 1 Correlations between CSF levels of PSD-95, SNAP-25, and neurogranin stratified by diagnostic groupCC BY · PubMed Central
Fig. 2 CSF levels of PSD-95 (A), SNAP-25 (C), and Neurogranin (E) in healthy controls (HC) and subjects with Alzheimer’s disease (AD), non-AD neurodegenerative diseases (NeuroDegen), and neurological controls (NeuroCtrl) from cohort I. CSF levels of PSD-95 (B), SNAP-25 (D), and neurogranin (F) by diagnosis. Solid green lines represent the median of the groups and dotted green lines represent the mean. Statistical analysis to determine differences between the individual NeuroDegen and NeuroCtrl diseases (B, D, and F) was not performed due to the large number of comparisons and small sample sizes, and graphs are included to provide information on outlier status
Fig. 2 CSF levels of PSD-95 (A), SNAP-25 (C), and Neurogranin (E) in healthy controls (HC) and subjects with Alzheimer’s disease (AD), non-AD neurodegenerative diseases (NeuroDegen), and neurological controls (NeuroCtrl) from cohort I. CSF levels of PSD-95 (B), SNAP-25 (D), and neurogranin (F) by diagnosis. Solid green lines represent the median of the groups and dotted green lines represent the mean. Statistical analysis to determine differences between the individual NeuroDegen and NeuroCtrl diseases (B, D, and F) was not performed due to the large number of comparisons and small sample sizes, and graphs are included to provide information on outlier statusCC BY · PubMed Central
Fig. 3 ROC-AUC curves for classification of AD vs HC (A), AD vs non-AD neurodegenerative diseases (B), and AD vs neurological controls (C) using PSD-95, SNAP-25, or neurogranin. The amyloid ß42/40 ratio and pTau181 are included as a reference. Graphs show AUC values with 95% confidence intervals
Fig. 3 ROC-AUC curves for classification of AD vs HC (A), AD vs non-AD neurodegenerative diseases (B), and AD vs neurological controls (C) using PSD-95, SNAP-25, or neurogranin. The amyloid ß42/40 ratio and pTau181 are included as a reference. Graphs show AUC values with 95% confidence intervalsCC BY · PubMed Central
Fig. 4 CSF levels of PSD-95 (A) and SNAP-25 (B) in healthy controls (HC) and subjects with AD, non-AD neurodegenerative diseases (NeuroDegen), and other neurological conditions (NeuroCtrl) from cohort II. PSD-95 (C) and SNAP-25 (D) levels in HC and AD subjects stratified by cognitive status. Asymptomatic refers to cognitively unimpaired subjects with positive CSF AD biomarkers. Solid green lines represent the median of the groups and dotted green lines represent mean
Fig. 4 CSF levels of PSD-95 (A) and SNAP-25 (B) in healthy controls (HC) and subjects with AD, non-AD neurodegenerative diseases (NeuroDegen), and other neurological conditions (NeuroCtrl) from cohort II. PSD-95 (C) and SNAP-25 (D) levels in HC and AD subjects stratified by cognitive status. Asymptomatic refers to cognitively unimpaired subjects with positive CSF AD biomarkers. Solid green lines represent the median of the groups and dotted green lines represent meanCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 100

Metadata

Authors
Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., Graham, D., & Arnold, S. E.
Affiliations
  • Harvard University (US)
  • Massachusetts General Hospital (US)
  • Quanterix (United States) (US)
  • Biogen (United States) (US)
Corresponding author
Kivisäkk, Pia
Venue
Alzheimer's Research & Therapy
Published
2022-04-23
Volume
14
Issue
1
Pages
58-58
ISSN
1758-9193 (ISSN-L)
OpenAlex
W4226497637
Cited by
98
References
32
Citations by year
2026: 17 · 2025: 32 · 2024: 35 · 2023: 12 · 2022: 2
FWCI
13.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (RF1AG059856, P30AG062421)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, cerebrospinal fluid biomarkers, synaptic proteins, PSD-95, SNAP-25, neurogranin, Simoa assay, synaptic dysfunction, cognitive decline, amyloid-beta, neurodegenerative diseases, presynaptic markers
MeSH terms
Disks Large Homolog 4 Protein, Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurodegenerative Diseases, Synaptosomal-Associated Protein 25, Neurogranin, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-022-01002-x
The paper
Kivisäkk, P., Carlyle, B. C., Sweeney, T., Quinn, J. P., Ramirez, C. E., Trombetta, B. A., Mendes, M., Brock, M., Rubel, C., Czerkowicz, J., Graham, D., & Arnold, S. E. (2022). Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-022-01002-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.